Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.
Karn T, Meissner T, Weber KE, Solbach C, Denkert C, Engels K, Fasching PA, Sinn BV, Schrader I, Budczies J, Marmé F, Müller V, Holtrich U, Gerber B, Schem C, Young BM, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Loibl S. Karn T, et al. Among authors: meissner t. Clin Cancer Res. 2020 Apr 15;26(8):1896-1904. doi: 10.1158/1078-0432.CCR-19-1954. Epub 2020 Jan 13. Clin Cancer Res. 2020. PMID: 31932495 Clinical Trial.
Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.
Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M. Meißner T, et al. Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4):a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul. Cold Spring Harb Mol Case Stud. 2017. PMID: 28679691 Free PMC article.
RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue.
Forster M, Mark A, Egberts F, Rosati E, Rodriguez E, Stanulla M, Bauerschlag D, Schem C, Maass N, Amallraja A, Murphy KK, Prouse BR, Sulaiman RA, Young BM, Mathiak M, Hemmrich-Stanisak G, Ellinghaus D, Weidinger S, Rosenstiel P, Arnold N, Leyland-Jones B, Williams CB, Franke A, Meißner T. Forster M, et al. Among authors: meissner t. Oncotarget. 2018 Aug 17;9(64):32362-32372. doi: 10.18632/oncotarget.25981. eCollection 2018 Aug 17. Oncotarget. 2018. PMID: 30190792 Free PMC article.
Case report: 16-yr life history and genomic evolution of an ER+ HER2- breast cancer.
Xu B, Amallraja A, Swaminathan P, Elsey R, Davis C, Theel S, Viet S, Petersen J, Krie A, Davies G, Williams CB, Ehli E, Meißner T. Xu B, et al. Among authors: meissner t. Cold Spring Harb Mol Case Stud. 2020 Dec 17;6(6):a005629. doi: 10.1101/mcs.a005629. Print 2020 Dec. Cold Spring Harb Mol Case Stud. 2020. PMID: 33008833 Free PMC article.
Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer.
Richter F, Henssen C, Steiert TA, Meissner T, Mehdorn AS, Röcken C, Franke A, Egberts JH, Becker T, Sebens S, Forster M. Richter F, et al. Among authors: meissner t. Int J Mol Sci. 2023 Jun 26;24(13):10673. doi: 10.3390/ijms241310673. Int J Mol Sci. 2023. PMID: 37445849 Free PMC article.
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M. Herth I, et al. Among authors: meissner t. Exp Hematol. 2013 Mar;41(3):231-40. doi: 10.1016/j.exphem.2012.10.018. Epub 2012 Nov 8. Exp Hematol. 2013. PMID: 23142220 Free article. Clinical Trial.
383 results